We considered both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) due to their physiological roles as therapeutic targets involved in the symptoms of Alzheimer’s disease, in the treatment of which the currently available drugs are AChE inhibitors. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.